Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Exosomes & Liquid Biopsies Europe 2018

Pierre Laurent's Biography

Pierre Laurent, Professor, Universite Paris Descartes

Prof. Pierre Laurent-Puig is Professor at the Paris Descartes University Medical School, France. He works within the Department of Biochemistry at the European Georges Pompidou Hospital Paris, where he is responsible for the Clinical Oncogenetic Unit in the Department of Genetics. Since 2004, he is also Director of the UMR-S1147 INSERM laboratory ‘Personalized Medicine, Pharmacogenomics and Therapeutic optimization’. He has been recently nominated as director of a comprehensive cancer centre CARPEM ( joining 2 University hospital of Paris Decartes University belonging to the Assistance Publique - Hôpitaux de Paris networrk. After his specialization in gastroenterology, liver disease and digestive tract cancer, Pr. Laurent-Puig focused on the characterization of somatic genetic lesions in cancer. His work has also identified new diagnostic and prognostic markers, and more recently, markers for resistance to chemotherapy and targeted therapy. Pr. Laurent-Puig has co-authored 46 educational articles and approximately 227 original scientific publications in international, peer-reviewed journals, including Nature, and Nature Genetics. Dr. Laurent-Puig is an active member of several professional organizations, including the Amercican association for Cancer Research (AACR) and the French Society of Hepatogastroenterology. He has both broad scientific expertise and experience in research team management and more generally, in the supervision of large organisations and projects.

Pierre Laurent Image

Liquid Biopsy in Colon Cancer

Thursday, 25 October 2018 at 14:30

Add to Calendar ▼2018-10-25 14:30:002018-10-25 15:30:00Europe/LondonLiquid Biopsy in Colon CancerExosomes and Liquid Biopsies Europe 2018 in Rotterdam, The NetherlandsRotterdam, The

RAS mutations are currently sought for in tumor samples, which takes a median of almost 3 weeks in western European countries. This creates problems in clinical situations that require urgent treatment and for inclusion in therapeutic trials that need RAS status for randomization. Analysis of circulating tumor DNA might help to shorten the time required to determine RAS mutational status prior to anti-EGFR antibody therapy for metastatic colorectal cancer. Here we compared plasma versus tissue RAS analysis in a large prospective multicenter cohort.

Add to Calendar ▼2018-10-24 00:00:002018-10-26 00:00:00Europe/LondonExosomes and Liquid Biopsies Europe 2018Exosomes and Liquid Biopsies Europe 2018 in Rotterdam, The NetherlandsRotterdam, The